ليتروزول تيڤع

Land: Israel

Sprog: arabisk

Kilde: Ministry of Health

Aktiv bestanddel:

LETROZOLE 2.5 MG

Tilgængelig fra:

TEVA PHARMACEUTICAL INDUST.LTD

ATC-kode:

L02BG04

Lægemiddelform:

TABLETS

Indgivelsesvej:

PER OS

Fremstillet af:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapeutisk gruppe:

LETROZOLE

Terapeutiske indikationer:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Autorisation dato:

2010-01-01